Radiopaedia Helpers

Citation Preceding Space

error

"reduced lung function of a mixed (obstructive and restrictive) pattern, with elevated residual volume ²², reduced forced expiratoy volume (FEV¹), reduced forced vital capacity (FVC), reduced diffusing capacity for carbon monoxide (DLCO))"

Line 34:161 · Citations must have a preceding space, e.g. needs evidence <sup>2</sup>. '<sup>1</sup>'

Isotope Notation

error

"One case has been described (c.2011), presenting as a hypermetabolic pulmonary nodule on 18F-FDG-PET with associated hypermetabolic axillary lymphadenopathy ⁷."

Line 83:100 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.

Acronyms

warning

"reduced lung function of a mixed (obstructive and restrictive) pattern, with elevated residual volume ²², reduced forced expiratoy volume (FEV¹), reduced forced vital capacity (FVC), reduced diffusing capacity for carbon monoxide (DLCO))"

Line 34:158 · 'FEV' has no definition. Spell it out if it's unfamiliar to the audience.

Accepted Abbreviations

warning

"One case has been described (c.2011), presenting as a hypermetabolic pulmonary nodule on 18F-FDG-PET with associated hypermetabolic axillary lymphadenopathy ⁷."

Line 83:33 · Check the abbreviation form against the style guide: 'c.2011'.

Number Formatting

warning

"One case has been described (c.2011), presenting as a hypermetabolic pulmonary nodule on 18F-FDG-PET with associated hypermetabolic axillary lymphadenopathy ⁷."

Line 83:34 · Check the number format against the style guide: '.2011'.

Headings Valid

warning

Expected headings

H1 Terminology
H1 Usage
H1 Epidemiology
H2 Risk factors
H2 Associations
H1 Clinical presentation
H2 Complications
H1 Diagnosis
H2 Diagnostic criteria
H2 Diagnostic clues
H1 Pathology
H2 Aetiology
H2 Location
H2 Classification
H2 Macroscopic appearance
H2 Microscopic appearance
H2 Immunophenotype
H2 Markers
H2 Genetics
H1 Radiographic features
H2 Plain radiograph
H2 Mammography
H2 Antenatal ultrasound
H2 Transoesophageal echocardiography
H2 Ultrasound
H2 CT
H3 Dual-energy CT
H2 Angiography (DSA)
H2 MRI
H2 CT/MRI
H2 Nuclear medicine
H3 PET-CT
H3 PET-MRI
H1 Radiology report
H1 Treatment and prognosis
H2 Complications
H1 History and etymology
H1 Differential diagnosis
H2 Clinical differential diagnosis
H1 Practical points
H1 See also

"Associations"

Line 42:1 · "Associations" is under the wrong parent heading (found under "Pathology").

"Complications"

Line 86:1 · "Complications" is under the wrong parent heading (found under "Treatment and prognosis").

Parentheses

suggestion

"reduced lung function of a mixed (obstructive and restrictive) pattern, with elevated residual volume ²², reduced forced expiratoy volume (FEV¹), reduced forced vital capacity (FVC), reduced diffusing capacity for carbon monoxide (DLCO))"

Line 34:41 · Use parentheses judiciously. There are at least 3 sets in this paragraph.

There Is

suggestion

"Pleuroparenchymal fibroelastosis usually shows a progressive clinical course and carries a poor prognosis. There is no specific therapy. Medical options with steroids, cyclophosphamide, azathioprine, N-acetylcysteine, azithromycin, sulfamethoxazole and trimethoprim may all be tried. Antifibrotics are ineffectual. In progressive cases, lung transplantation may be required."

Line 85:111 · Don't start a sentence with 'There is'.

Oxford Comma

suggestion

"Pleuroparenchymal fibroelastosis usually shows a progressive clinical course and carries a poor prognosis. There is no specific therapy. Medical options with steroids, cyclophosphamide, azathioprine, N-acetylcysteine, azithromycin, sulfamethoxazole and trimethoprim may all be tried. Antifibrotics are ineffectual. In progressive cases, lung transplantation may be required."

Line 85:222 · Use the Oxford comma in 'azithromycin, sulfamethoxazole and trimethoprim'.

Lint: pleuroparenchymal-fibroelastosis